Results 111 to 120 of about 52,382 (294)

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)

Haematologica, 2011
Background Anemia is an established negative prognostic factor in myelodysplastic syndromes but the relationship between its degree and clinical outcome is poorly defined.
Luca Malcovati, Matteo G. Della Porta, Corinna Strupp, Ilaria Ambaglio, Andrea Kuendgen, Kathrin Nachtkamp, Erica Travaglino, Rosangela Invernizzi, Cristiana Pascutto, Mario Lazzarino, Ulrich Germing, Mario Cazzola   +11 more
doaj   +1 more source

CLINICAL APPLICABILITY OF PROPOSED ALGORITHM FOR IDENTIFYING INDIVIDUALS AT RISK FOR HEREDITARY HEMATOLOGIC MALIGNANCIES [PDF]

, 2017
Over the past decade, more than 12 genes have been identified to cause hereditary predispositions to hematologic malignancies. These syndromes are characterized by an increased risk to develop myelodysplastic syndrome (MDS), acute myeloid leukemia (AML),
Clifford, Maggie
core   +1 more source

Impact of CD34+ cell dose on outcomes of related allogeneic PBSCT in adult AML patients

British Journal of Haematology, EarlyView.
Summary CD34+ cell dose is believed to impact the outcomes of allogeneic peripheral blood stem cell transplantation (PBSCT), yet the optimal dose remains unclear. We retrospectively reviewed 2407 adult patients with acute myeloid leukaemia who underwent their first related PBSCT between 2000 and 2019.
Yusuke Toda, Tomoyasu Jo, Yasuyuki Arai, Kaito Harada, Masamitsu Yanada, Takahiro Fukuda, Satoshi Yoshihara, Noriko Doki, Naoyuki Uchida, Yasuo Mori, Yuta Hasegawa, Yukio Kondo, Toshiro Kawakita, Tetsuya Eto, Tetsuya Nishida, Masatsugu Tanaka, Makoto Onizuka, Katsuhiro Shono, Masayuki Hino, Tatsuo Ichinohe, Yoshiko Atsuta, Takaaki Konuma   +21 more
wiley   +1 more source

Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party

Haematologica, 2014
Acquired chromosomal abnormalities are important prognostic factors in patients with myelodysplastic syndromes treated with supportive care and with disease-modifying therapeutic interventions, including allogeneic hematopoietic stem cell transplantation.
Francesco Onida, Ronald Brand, Anja van Biezen, Michel Schaap, Peter A. von dem Borne, Johan Maertens, Dietrich W. Beelen, Enric Carreras, Emilio P. Alessandrino, Liisa Volin, Jürgen H.E. Kuball, Angela Figuera, Jorge Sierra, Jürgen Finke, Nicolaus Kröger, Theo de Witte   +15 more
doaj   +1 more source

Day‐30 IL1RL1, CXCL9 and REG3α are prognostic for survival after mismatched unrelated donor transplantation

British Journal of Haematology, EarlyView.
Summary While plasma‐derived proteins have emerged as potential biomarkers for prognosis after haematopoietic stem cell transplantation (HSCT), there are insufficient data assessing if established proteins interleukin 1 receptor‐like 1 (IL1RL1), chemokine ligand 9 (CXCL9) and regenerating islet‐derived 3‐α (REG3α) retain their utility in the mismatched
Trent Wang, Anna C. Ferreira, Nasheed M. Hossain, Denggang Fu, Elizabeth G. Hill, Antonio M. Jimenez Jimenez, Cara Benjamin, Krishna V. Komanduri, Sophie Paczesny   +8 more
wiley   +1 more source

Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide

Haematologica, 2019
In myelodysplastic syndromes with a partial deletion of the long arm of chromosome 5, del(5q), lenalidomide is believed to reverse anergic T-cell immunity in the bone marrow resulting in suppression of the del(5q) clone.
Thorben Mährle, Nuray Akyüz, Pim Fuchs, Nicola Bonzanni, Donjete Simnica, Ulrich Germing, Anne Marie Asemissen, Johann Christoph Jann, Florian Nolte, Wolf-Karsten Hofmann, Daniel Nowak, Mascha Binder   +11 more
doaj   +1 more source

Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival

Brain Pathology, EarlyView.
Untargeted multiomic profiling of cerebrospinal fluid reveals that proteomic, but not lipidomic, signatures robustly distinguish ALS patients from controls and stratify individuals by survival, highlighting marked molecular differences between short survival and long survival disease.
Sergio Roca‐Pereira, Yaiza López‐Sampere, Pol Mengod‐Soler, Mario Peña‐Fonteboa, Carla Marco, Alejandro Caravaca‐Puchades, Raúl Domínguez, Juan Francisco Vázquez‐Costa, Enrique Santamaría, Joaquín Fernández‐Irigoyen, María J. Colomina, Isabel León Moreno, Antonio Martínez Yélamos, Sergio Martínez Yélamos, Gabriel Santpere, Elia Obis, Manuel Portero‐Otín, Gerard Piñol‐Ripoll, Mónica Povedano, Pol Andrés‐Benito   +19 more
wiley   +1 more source

Clonal evolution in myelodysplastic syndromes

Nature Communications, 2017
Myelodysplastic syndromes are a broad group of haematopoietic malignancies that often progress to acute myeloid leukaemia. Here, the authors show that linear and branched evolution occurs within myelodysplastic syndrome and these patterns can be impacted
Pedro da Silva-Coelho, Leonie I. Kroeze, Kenichi Yoshida, Theresia N. Koorenhof-Scheele, Ruth Knops, Louis T. van de Locht, Aniek O. de Graaf, Marion Massop, Sarah Sandmann, Martin Dugas, Marian J. Stevens-Kroef, Jaroslav Cermak, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Theo de Witte, Nicole M. A. Blijlevens, Petra Muus, Gerwin Huls, Bert A. van der Reijden, Seishi Ogawa, Joop H. Jansen   +22 more
doaj   +1 more source

Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study

Haematologica, 2009
Background The diagnosis of myelodysplastic syndromes is not always straightforward when patients lack specific diagnostic markers, such as blast excess, karyotype abnormality, and ringed sideroblasts.Design and Methods We designed a flow cytometry ...
Kiyoyuki Ogata, Matteo G. Della Porta, Luca Malcovati, Cristina Picone, Norio Yokose, Akira Matsuda, Taishi Yamashita, Hideto Tamura, Junichi Tsukada, Kazuo Dan   +9 more
doaj   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source